Regidor Pedro-Antonio, Schindler Adolf E
Exeltis West Europe & Germany, Ismaning, Germany.
Institut für Medizinische Forschung, Essen, Germany.
Oncotarget. 2017 Aug 3;8(47):83334-83342. doi: 10.18632/oncotarget.19833. eCollection 2017 Oct 10.
Data have demonstrated that COCs, besides offering a satisfactory and safe contraception, offer a variety of non-contraceptive health benefits and therapeutic positive aspects. Many prescribes and users, however, do not realize these positive aspects especially the non-contraceptive health benefits. While the contraceptive use is the primary indication for COC use for most women, these users should be advised in regard of the non-contraceptive benefits when contraception is discussed and prescribed. Using COCs specifically for non-contraceptive indications is an off-label use in many clinical situations (only some exceptions as e.g. acne vulgaris in some countries are allowed clinical entities for the use of these drugs). Therefore, appropriate discussions with the patient regarding this fact should performed and documented by the prescribing physicians. Independent of the off-label situation, COCs containing the newer progestogens dienogest and drospirenone with their antiandrogenic and antimineralocorticoid health benefits play an important role in the management of many diseases and their use should therefore be considered by clinician's. This review will focus on the effects of these COCs on the endometrium, the skin, the fat tissue and the premenstrual syndrome.
数据表明，复方口服避孕药（COCs）除了提供令人满意且安全的避孕效果外，还具有多种非避孕方面的健康益处和治疗优势。然而，许多开处方的医生和使用者并未意识到这些积极方面，尤其是非避孕的健康益处。虽然对于大多数女性而言，避孕是使用复方口服避孕药的主要指征，但在讨论和开出处方时，应向这些使用者告知其非避孕益处。在许多临床情况下，专门将复方口服避孕药用于非避孕指征属于超说明书用药（仅在某些国家，如寻常痤疮等一些情况允许使用这些药物作为临床实体）。因此，开处方的医生应与患者就这一事实进行适当讨论并记录在案。无论是否属于超说明书用药情况，含有新型孕激素地诺孕素和屈螺酮的复方口服避孕药因其具有抗雄激素和抗盐皮质激素的健康益处，在许多疾病的管理中发挥着重要作用，因此临床医生应予以考虑。本综述将聚焦于这些复方口服避孕药对子宫内膜、皮肤、脂肪组织和经前综合征的影响。
